Scribe Therapeutics Inc. (SCTX) vs TriSalus Life Sciences, Inc. (TLSI)

A side-by-side comparison of Scribe Therapeutics Inc. and TriSalus Life Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

SCTX

Scribe Therapeutics Inc.

$267M

$16.48HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT

TLSI

TriSalus Life Sciences, Inc.

$262M

$4.25HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT

Total return — SCTX vs TLSI

growth of $100 · dividends reinvested · last 1y

SCTX +8.1% (+8.1%/yr)TLSI +3.3% (+3.3%/yr)SCTX compounded faster over this window

SCTX TLSI

Metrics side by side

Total return (annualized)

Metric	SCTX	TLSI
Total return (1Y)	N/A	-5.17%
Total return CAGR (3Y)	N/A	-3.41%
Total return CAGR (5Y)	N/A	-15.05%

SCTX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full SCTX analysis Full TLSI analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.